Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)
Dynavax Technologies Corporation is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors are keying on: $15.50 per share in cash—a bid that reframes the near-term outlook for DVAX stock from “earnings and pipeline execution” to “deal timeline and closing risk.” Sanofi+1